NCT00417716

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Asociación para Evitar la Ceguera en México · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

Detailed description

A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.

Conditions

• Diabetes Mellitus Type 2
• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Intravitreal Bevacizumab

Timeline

• Start date: 2005-09-01
• Primary completion: 2005-09-01
• Completion: 2006-05-01
• First posted: 2007-01-04
• Last updated: 2024-06-03

Locations

1 site across 1 country: Mexico